Putting GlaxoSmithKline to the test over paroxetine

BMJ (Online)

Volumn 347, Issue , 2013, Pages

  Doshi, Peter ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR;

ADOLESCENT; AUTOMUTILATION; CHILD; CLINICAL TRIAL (TOPIC); DEPRESSION; DRUG EFFICACY; DRUG INDUSTRY; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERABILITY; HEALTH HAZARD; HUMAN; LAW SUIT; MEDICAL LITERATURE; PRIORITY JOURNAL; PUBLIC HEALTH; PUBLICATION; REGISTER; SHORT SURVEY; SUICIDAL BEHAVIOR; UNITED KINGDOM; UNITED STATES;

ACCESS TO INFORMATION; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CHILD; CLINICAL TRIALS AS TOPIC; DRUG INDUSTRY; GREAT BRITAIN; HUMANS; PAROXETINE; UNITED STATES;

EID: 84888258828     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.f6754     Document Type: Short Survey

References (18)

1. Keller MB, Ryan ND, Strober M, Klein RG, Kutcher SP, Birmaher B, et al. Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. J Am Acad Child Adolesc Psychiatry 2001;40:762-72.
2. Kmietowicz Z. GSK backs campaign for disclosure of trial data. BMJ 2013;346:f819.
3. Hawkes N. Industry and drug regulators disagree on which data should remain confidential. BMJ 2013;347f5390.
4. Nisen P, Rockhold F. Access to patient-level data from GlaxoSmithKline clinical trials. N Engl J Med 2013;369:475-8.
5. Jureidini J, Tonkin A. Paroxetine in major depression. J Am Acad Child Adolesc Psychiatry 2003;42:514, author reply 514-5.
6. Jureidini JN, McHenry LB, Mansfield PR. Clinical trials and drug promotion: selective reporting of study 329. Int J Risk Saf Med 2008;20:73-81.
7. Zito JM, Safer DJ, dosReis S, Gardner JF, Soeken K, Boles M, et al. Rising prevalence of antidepressants among US youths. Pediatrics 2002;109:721-7.
8. Olfson M, Marcus SC, Druss BG. Effects of food and drug administration warnings on antidepressant use in a national sample. Arch Gen Psychiatry 2008;65:94-101.
9. United States ex rel. Greg Thorpe, et al v. GlaxoSmithKline plc, and GlaxoSmithKline llc. United States' complaint. C.A. No. 11-10398-RWZ. 2011 www.justice.gov/opa/documents/gsk/us-complaint.pdf.
10. Newman M. The rules of retraction. BMJ 2010;341:c6985.
11. Doshi P, Dickersin K, Healy D, Vedula SS, Jefferson T. Restoring invisible and abandoned trials: a call for people to publish the findings. BMJ 2013;346:f2865.
12. Civil Action No 04-V-5304 MGC. People of the State of New York against GlaxoSmithKline, plc and SmithKline Beecham Corporation. Consent order & judgment. 2004. www.ag.ny.gov/sites/default/files/press-releases/archived/ aug26a-04-attach1.pdf.
13. Shannon J. Unlocking access to clinical trial data - what are we afraid of? Huffington Post 2013 Sep 9. www.huffingtonpost.co.uk/james-shannon/clinical- trial-data-b-3859734.html.
14. GlaxoSmithKline CEO on increasing transparency of clinical trials. Fox Business 2013 Oct 10, http://video.foxbusiness.com/v/2735629915001/ glaxosmithkline-ceo-on-increasing-transparency-of-clinical-trials/.
15. GlaxoSmithKline. Data sharing agreement. https://clinicalstudydata.gsk. com/Documents/DATA-SHARING-AGREEMENT.pdf.
16. Vallance P, Chalmers I. Secure use of individual patient data from clinical trials. Lancet 2013;382:1073-4.
17. Mello MM, Francer JK, Wilenzick M, Teden P, Bierer BE, Barnes M. Preparing for responsible sharing of clinical trial data. N Engl J Med 2013;369:1651-8.
18. US Department of Justice. GlaxoSmithKline to plead guilty and pay $3 billion to resolve fraud allegations and failure to report safety data. 2012. www.justice.gov/opa/pr/2012/July/12-civ-842.html.